Navigation Links
Should high-dose interleukin-2 continue to be the treatment of choice for metastatic melanoma?

New Rochelle, NY, July 26, 2012 Administering high-doses of interleukin-2 (IL-2) has been the preferred treatment for patients with stage IV metastatic melanoma. An article published in the current issue of Cancer Biotherapy and Radiopharmaceuticals, a peer-reviewed journal from Mary Ann Liebert, Inc. (, explores whether or not this regimen is still the most effective. The article is available free online at the Cancer Biotherapy and Radiopharmaceuticals website (

In the article "Should High-Dose Interleukin-2 Still Be the Preferred Treatment for Patients with Metastatic Melanoma?" ( Robert Dillman and colleagues at the Hoag Institute for Research and Education and Hoag Family Cancer Institute, Newport Beach, CA concluded that until long-term survival data for some of the newer drugs are available, patients with stage IV metastatic melanoma who are well enough to be given intensive IL-2 therapy should receive it initially, either alone or in combination with one of the newer therapeutic agents.

"This is an important article that puts into perspective the reasons why IL-2 should continue to be the initial therapy in patients with metastatic melanoma," says Editor Donald J. Buchsbaum, PhD, Division of Radiation Biology, Department of Radiation Oncology, University of Alabama at Birmingham.

Contact: Vicki Cohn
914-740-2100 x2156
Mary Ann Liebert, Inc./Genetic Engineering News

Page: 1

Related biology news :

1. Happy Fathers Day! Another reason why dads and hopeful dads should quit smoking now
2. Countries should implement inclusive wealth accounting
3. President, CEO Leppävuori, VTT: Finland should create a national bioeconomy strategy
4. Reproductive health providers should discuss environmental exposure risks with patients
5. Should we play hide-and-go-seek with our childrens vegetables?
6. Global CO2 emissions continue to increase
7. Cell Press journals continue to deliver high impact
8. Monarch butterflies down again this year as decline continues, says Texas A&M expert
9. Powerful class of antioxidants may be potent Parkinsons treatment
10. ECGs administered by paramedics can speed treatment for severe heart attacks
11. Reorganizing brain could lead to new stroke, tinnitus treatments
Post Your Comments:
Related Image:
Should high-dose interleukin-2 continue to be the treatment of choice for metastatic melanoma?
(Date:10/5/2015)... , October 5, 2015 ... update for NXT-ID, Inc. (NASDAQ: NXTD ), a ... market. --> ) releases ... (NASDAQ: NXTD ), a biometric authentication company focused ... SoundView Technology Group ( ) releases ...
(Date:9/30/2015)... , Sept. 30, 2015  The U.S. Court ... issued another key ruling in favor of Crossmatch ... Korean fingerprint scanner company Suprema and its U.S. partner ... 1930, a trade provision that declares it unlawful to ... by infringing two of Crossmatch,s patents, the 5,900,993 patent ...
(Date:9/28/2015)... NEW YORK , Sept. 28, 2015 ... platform, announced today that its expedited traveler ...  CLEAR,s innovative platform transforms travel, bringing a ... for its members. "CLEAR offers ... which enhances customer service," said Jim ...
Breaking Biology News(10 mins):
(Date:10/12/2015)... Carolina (PRWEB) , ... October 12, 2015 , ... Spirax ... announce the release of the CSM-C 600 compact clean steam generator . ... steam that meets the requirements of HTM2031, HTM2010, and EN285 standards. The CMS-C ...
(Date:10/12/2015)... de octubre de 2015 El 8 de ... un récord en el congreso con su declaración acerca ... International Plasma Awareness Week (IPAW), que se celebrará del ... por la Plasma Protein Therapeutics Association (PPTA) ... , Aumentar la concienciación mundial acerca de la ...
(Date:10/12/2015)... Belgium , Oct. 12, 2015 VolitionRx ... from a completed clinical study of its NuQ ® ... in the online issue of Clinical Epigenetics , the ... was conducted in collaboration with Lund ... Roland Andersson , MD, PhD, Professor of Surgery and Vice-Dean, ...
(Date:10/10/2015)... ANNAPOLIS, Maryland , le 10 octobre 2015 ... (D-CA) a intégré dans le Registre du Congrès ... internationale annuelle pour la sensibilisation autour du plasma ... L,IPAW est sponsorisée par la Plasma Protein ... et vise à : , Sensibiliser ...
Breaking Biology Technology: